U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341737) titled 'SL-28 for Advanced Solid Tumours' on Nov. 17, 2025.
Brief Summary: Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to d...